Track record · closed signal

Grifols, S.A. (GRFS) — closed signal from September 16, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 15, 2025.

Predicted vs. what happened

GRFS price · publication thesis → realized outcomesplit-adjusted
$9.95 Published $11.74 Target $9.03 Window close $10.23 Peak
$9.80 – $10.00Entry zone — fair-value band
$9.95Published — price the day we called it
$11.74Target — the price the thesis aimed for
$10.23Peak — highest point inside the window, not a realized return
$9.03Window close — end-of-window price, context only

What happened

Partial

Reached 16% of the predicted growth at its peak, without hitting the target.

Peak price
$10.23
peak on October 2, 2025 — not a realized return
Peak gain
+2.9%
peak, from the publication price
Window close
$9.03
end-of-window price, context only
Days to target
Window
September 16, 2025 – December 15, 2025

The thesis — published September 16, 2025

Predicted growth
+18%
over the measurement window
Target price
$11.74
the price the thesis aimed for
Entry zone
$9.80 – $10.00
the fair-value band we waited for
Price at publication
$9.95
published September 16, 2025
Confidence
60%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Grifols looks like a value idea that could bounce back after a sharp drop. The price seems unusually beaten down. The company plans to roughly double plasma capacity in Europe around 09-11, which could lift profits. Independent checks suggest the shares look cheap. Treat this as a 3-month rebound plan with clear exits because debt levels raise the risk, and only if execution stays on track.

Primary drivers

  • Price looks unusually beaten down, which can set up a near-term rebound.
  • Europe capacity plan around 09-11 aims to roughly double plasma output.
  • Independent value checks and a noted Buy rating suggest the stock is cheap.
  • Short-term trade idea with strict exit rules to control downside risk.

How it played out

GRFS: target was not reached

Lyra published GRFS at 9.95 on 2025-09-16 as a short-term rebound idea with 18% expected growth. The thesis pointed to a beaten-down price, a Europe plasma capacity plan around 09-11, independent value checks, a noted Buy rating, and strict exit rules because debt raised the risk.

Inside the window, GRFS peaked at 10.23 on 2025-10-02, a 2.9% gain. That stayed below the 11.74 target. It never got there. By 2025-12-15, the stock ended at 9.03. The thesis missed on the measured price outcome.

What happened during the window

On 2025-11-04, Grifols reported third-quarter revenue of 1,865 million euros, up 9.1%, and said nine-month revenue was 5,542 million euros. The article also said adjusted EBITDA through September was 1,358 million euros, up 11.2%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.